Anti-Angiogenesis Therapy for Melanoma
作者： Roberta Ferraldeschi , Paul Lorigan
DOI: 10.1007/978-1-60761-433-3_21
关键词:
摘要: Since the work of Judah Folkman in 1970s, it is now widely accepted that angiogenesis essential for tumor growth. Neovascularization considered an step multistage progression melanoma. In this chapter, we briefly describe mechanisms and provide overview emerging anti-angiogenic strategies melanoma treatment.
springer.com
sci-hub.st 参考文章(113)
Susan E. Krown, Donna Niedzwiecki, Wen-Jen Hwu, Lydia Hodgson, Alan N. Houghton, Frank G. Haluska, , Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain Cancer. ,vol. 107, pp. 1883- 1890 ,(2006) , 10.1002/CNCR.22239
Peter Carmeliet, Rakesh K. Jain, Angiogenesis in cancer and other diseases Nature. ,vol. 407, pp. 249- 257 ,(2000) , 10.1038/35025220
Wen-Jen Hwu, Eric Lis, Jennifer H. Menell, Katherine S. Panageas, Lynne A. Lamb, Janene Merrell, Linda J. Williams, Susan E. Krown, Paul B. Chapman, Philip O. Livingston, Jedd D. Wolchok, Alan N. Houghton, Temozolomide plus thalidomide in patients with brain metastases from melanoma Cancer. ,vol. 103, pp. 2590- 2597 ,(2005) , 10.1002/CNCR.21081
J. Blake Bartlett, Keith Dredge, Angus G. Dalgleish, The evolution of thalidomide and its IMiD derivatives as anticancer agents Nature Reviews Cancer. ,vol. 4, pp. 314- 322 ,(2004) , 10.1038/NRC1323
Selma Ugurel, Gunter Rappl, Wolfgang Tilgen, Uwe Reinhold, Increased Serum Concentration of Angiogenic Factors in Malignant Melanoma Patients Correlates With Tumor Progression and Survival Journal of Clinical Oncology. ,vol. 19, pp. 577- 583 ,(2001) , 10.1200/JCO.2001.19.2.577
Weibo Cai, Xiaoyuan Chen, Anti-Angiogenic Cancer Therapy Based on Integrin αvβ3 Antagonism Anti-cancer Agents in Medicinal Chemistry. ,vol. 6, pp. 407- 428 ,(2006) , 10.2174/187152006778226530
John M.L. Ebos, Christina R. Lee, William Cruz-Munoz, Georg A. Bjarnason, James G. Christensen, Robert S. Kerbel, Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis Cancer Cell. ,vol. 15, pp. 232- 239 ,(2009) , 10.1016/J.CCR.2009.01.021
P Ciotti, M L Rainero, G Nicol??, B Spina, C Garr??, F Casabona, P L Santi, G Bianchi-Scarr??, Cytokine expression in human primary and metastatic melanoma cells: analysis in fresh bioptic specimens. Melanoma Research. ,vol. 5, pp. 41- 47 ,(1995) , 10.1097/00008390-199502000-00005
Paul A. Renhowe, Sabina Pecchi, Cynthia M. Shafer, Timothy D. Machajewski, Elisa M. Jazan, Clarke Taylor, William Antonios-McCrea, Christopher M. McBride, Kelly Frazier, Marion Wiesmann, Gena R. Lapointe, Paul H. Feucht, Robert L. Warne, Carla C. Heise, Daniel Menezes, Kimberly Aardalen, Helen Ye, Molly He, Vincent Le, Jayesh Vora, Johanna M. Jansen, Mary Ellen Wernette-Hammond, Alex L. Harris, Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors. Journal of Medicinal Chemistry. ,vol. 52, pp. 278- 292 ,(2009) , 10.1021/JM800790T
Krystyna Teichert-Kuliszewska, Peter C Maisonpierre, Nina Jones, Andrew IM Campbell, Zubin Master, Michelle P Bendeck, Kari Alitalo, Daniel J Dumont, George D Yancopoulos, Duncan J Stewart, Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2. Cardiovascular Research. ,vol. 49, pp. 659- 670 ,(2001) , 10.1016/S0008-6363(00)00231-5